
Palborest 75mg Tablet
Marketer
MSN Laboratories
Salt Composition
Palbociclib (75mg)
Overview Palborest 75mg Tablet
Estrogen receptor-positive, HER2-negative metastatic breast cancer is treated with the 75mg Palborest tablet, administered alongside hormonal cancer therapies. For optimal absorption, take this medication with food at the same time each day, as directed by your oncologist. Dosage and frequency are individualized and may adjust over time based on your response to treatment. Strictly adhere to your prescribed regimen; improper use or overdose can lead to severe adverse reactions. Therapeutic effects may not be apparent for weeks or months; discontinue use only under your doctor's guidance. Common side effects include nausea, alopecia, skin reactions, vomiting, and diarrhea. Palborest may suppress blood cell production, increasing infection risk. Report any signs of infection (fever, chills, weakness), bleeding/bruising, or epistaxis immediately. Dizziness may occur; avoid driving or activities requiring alertness if affected. Prior to commencing therapy, inform your doctor of any existing heart, liver, or kidney conditions, and all other medications, especially anti-infectives, as drug interactions are possible. This medication is contraindicated during pregnancy and breastfeeding. Reliable contraception for both partners is crucial throughout the treatment period.
Primary Ingredients of Palborest 75mg Tablet
No text was provided to rewrite.
Uses of Palborest 75mg Tablet
Malignant breast tumor
Major Benefits of Palborest 75mg Tablet:
Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. It's recommended to take the Palborest 75mg Tablet with a meal.
Common Side effects of Palborest 75mg Tablet:
- Decreased blood cells (red cells, white cells, and platelets)
- Fatigue
- Hair loss
- Rash
- Vomiting
- Diarrhea
- Nausea
- Decreased appetite
- Infection
- Decreased white blood cell count
- Stomatitis (Inflammation of the mouth)
- Anemia (low number of red blood cells)
- Weakness
- Fever
How to use Palborest 75mg Tablet:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment schedule. Ingest the 75mg Palborest tablet whole; avoid crushing, chewing, or fracturing it. It should be taken with a meal.
How Palborest 75mg Tablet works:
Palborest 75mg tablets are an anti-neoplastic agent. Its mechanism involves blocking cyclin-dependent kinases 4 and 6, key proteins driving cellular replication. By inhibiting these signaling molecules, Palborest arrests cancer cell growth. Furthermore, it specifically targets estrogen receptor-positive breast cancers by interfering with their cell cycle progression.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
The safety of combining alcohol with Palborest 75mg Tablets is undetermined. Seek medical advice before mixing them.
PregnancyCONSULT YOUR DOCTOR
Use of Palborest 75mg tablets is contraindicated during pregnancy due to established risks to the fetus. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Physician consultation is essential.
Breast feedingUNSAFE
Lactation is contraindicated with Palborest 75mg Tablets due to potential infant toxicity. Evidence indicates the medication may harm a nursing child.
DrivingUNSAFE
Taking a 75mg Palborest tablet might lead to side effects that impair driving ability. Some individuals experience tiredness. If this occurs, operate vehicles or machinery with extra care.
KidneySAFE IF PRESCRIBED
For patients with kidney disease, Palborest 75mg tablets are considered safe and require no dosage modification.
LiverCAUTION
Individuals with liver impairment should exercise caution when using Palborest 75mg tablets. Dosage modification may be necessary. Physician consultation is advised.
What if you forget to take Palborest 75mg Tablet :
NA
Facts to Know About Palborest 75mg Tablet
| Label | Value |
|---|---|
| Chemical Type | Piperazine-pyridines |
| Developing Habits | No. |
| Type of Therapy | Cancer Medications |
| Behavioral Class | CDK Inhibitor |
